Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 4 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Breast Neoplasms 208Neoplasms 130Polycystic Ovary Syndrome 107Carcinoma, Hepatocellular 82Colorectal Neoplasms 77Prostatic Neoplasms 70Stomach Neoplasms 55Lung Neoplasms 51Precursor Cell Lymphoblastic Leukemia-Lymphoma 49Carcinoma, Non-Small-Cell Lung 43Pain, Postoperative 42Pancreatic Neoplasms 41Head and Neck Neoplasms 38Pain 37Liver Neoplasms 36Leukemia, Myeloid, Acute 32Leiomyoma 32Keratosis, Actinic 31Colonic Neoplasms 31Recurrence 30Neoplasm Metastasis 29Multiple Myeloma 28Infertility 28Brain Neoplasms 28Uterine Cervical Neoplasms 26Urinary Bladder Neoplasms 24Ovarian Neoplasms 24Lymphoma 24Esophageal Neoplasms 23Obesity 22

Interventions

candesartan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × OTHER × Essential Hypertension × Clear all
NCT01629225 2014-11-18

GRK4 Polymorphisms Blood Pressure Response to Candesartan

Third Military Medical University

Phase 4 Unknown
500 enrolled
Endocrine

Essential Hypertension, Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡